Aron Tendler
Research Subjects
Aron Tendler has a total of 277 co-authors. Here are the top co-authors by number of shared publications:
Yiftach Roth
27 shared publicationsAbraham Zangen
Department of Life Sciences, Ben Gurion University of the Negev, Beersheba, Israel
16 shared publications- Abraham Zangen
Faculty of Life Sciences, Ben-Gurion University of the Negev, Be’er Sheva, Israel
14 shared publications Tal Harmelech
GrayMatters Health
14 shared publicationsLaura DeLuca
10 shared publications- Elyssa Sisko
Advanced Mental Health Care Inc., United States
8 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Elsevier in Brain Stimulation
Clinical efficacy of accelerated vs. standard H1-coil TMS dosing: a prospective, multisite, 12-month durability study
- 30 October 2026
- Published by Elsevier in Brain Stimulation
Open AccessClinical efficacy of accelerated vs. standard H1-coil TMS dosing: a prospective, multisite, 12-month durability study
- Open Access
- 21 September 2026
- Published by Elsevier in Transcranial Magnetic Stimulation
- Vol. 8
Re: Weber CL, Segal SK, Gruschkus SK, Sukumar V, Ivany CG. Changes in core symptoms of Posttraumatic Stress Disorder associated with a novel sequential bilateral protocol: A case series. Transcranial Magnetic Stimulation. 2026;6:100211.
- 21 September 2026
- Published by Elsevier in Transcranial Magnetic Stimulation
- Vol. 8
Open AccessRe: Weber CL, Segal SK, Gruschkus SK, Sukumar V, Ivany CG. Changes in core symptoms of Posttraumatic Stress Disorder associated with a novel sequential bilateral protocol: A case series. Transcranial Magnetic Stimulation. 2026;6:100211.
- Open Access
- 30 April 2026
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 17, 1804685
Case Report: Prism for PTSD in severe traumatic brain injury with psychiatric comorbidities: two cases
Background: Traumatic brain injury (TBI) with post-traumatic stress disorder (PTSD) is treatment-resistant, with conventional psychotherapy showing limited efficacy due to neurocognitive impairments. Case Summary: We report two patients with severe TBI and psychiatric comorbidities treated with Prism neurofeedback. Case 1: 44-year-old female, 35 years post-childhood TBI, with agoraphobia and hyperacusis, achieved 42% PTSD reduction and substantial functional gains (social reintegration, independent driving) sustained through 4-month follow-up. Case 2: 40-year-old male, 3.5 years post-adult TBI with bipolar II disorder and severe PTSD (PCL-5 = 62), achieved 90% PTSD reduction with complete remission sustained at 1-month follow-up, enabling return to work and family system transformation. Both patients developed personalized regulatory strategies and maintained gains without relapse. Conclusions: Prism neurofeedback demonstrates clinically meaningful outcomes in severe TBI-PTSD where traditional psychotherapy shows limited efficacy. The intervention’s circumvention of cognitive processing demands may explain the favorable outcomes. Controlled trials are warranted.
- 30 April 2026
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 17, 1804685
Open AccessCase Report: Prism for PTSD in severe traumatic brain injury with psychiatric comorbidities: two cases
Background: Traumatic brain injury (TBI) with post-traumatic stress disorder (PTSD) is treatment-resistant, with conventional psychotherapy showing limited efficacy due to neurocognitive impairments. Case Summary: We report two patients with severe TBI and psychiatric comorbidities treated with Prism neurofeedback. Case 1: 44-year-old female, 35 years post-childhood TBI, with agoraphobia and hyperacusis, achieved 42% PTSD reduction and substantial functional gains (social reintegration, independent driving) sustained through 4-month follow-up. Case 2: 40-year-old male, 3.5 years post-adult TBI with bipolar II disorder and severe PTSD (PCL-5 = 62), achieved 90% PTSD reduction with complete remission sustained at 1-month follow-up, enabling return to work and family system transformation. Both patients developed personalized regulatory strategies and maintained gains without relapse. Conclusions: Prism neurofeedback demonstrates clinically meaningful outcomes in severe TBI-PTSD where traditional psychotherapy shows limited efficacy. The intervention’s circumvention of cognitive processing demands may explain the favorable outcomes. Controlled trials are warranted.
- Open Access
- 11 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (6) , 2122
Real-Time EEG-Derived Amygdala Neurofeedback for Post-Traumatic Stress Disorder: A Clinical Case Series
Background: Post-traumatic stress disorder (PTSD) affects millions globally, with 40–50% of patients not responding adequately to first-line treatments. Prism neurofeedback, an FDA-cleared electroencephalography (EEG)-based system targeting amygdala-derived biomarkers, has demonstrated efficacy in randomized controlled trials (RCTs) and multicenter studies. Real-world implementation data from community clinical practice remain limited. Objective: To evaluate clinical outcomes and patient-developed self-regulation strategies of Prism neurofeedback in patients with PTSD in community clinical practice. Methods: Retrospective case series of 28 consecutive patients with PTSD treated with Prism neurofeedback in a community psychiatry practice. The primary outcome was change in PTSD Checklist for DSM-5 (PCL-5) from baseline to end of treatment. Results: Twenty-one of 28 patients (75.0%) completed treatment. Mean PCL-5 reduction was 37.0 ± 18.2 points (Cohen’s d = 2.03). Response rates were 100% for any improvement and 90.5% for clinically significant improvement (≥10-point reduction). Five patients (23.8%) achieved excellent response with ≥50-point reduction. Limited follow-up data (1–3 months post-treatment) were available for three patients; two of three (67%) exceeded their end-of-treatment gains. Four patients receiving booster sessions showed continued improvement. Limitations: The uncontrolled, retrospective design precludes causal attribution of improvements to the intervention versus placebo effects or regression to the mean. The 25% early discontinuation rate may introduce attrition bias. Durability data are available for only three patients. Conclusions: This case series provides real-world evidence supporting the feasibility and potential clinical utility of Prism neurofeedback in community practice, with outcomes comparable to controlled studies and preliminary evidence of durable treatment effects. These findings complement existing RCT evidence by demonstrating successful implementation outside research settings.
- 11 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (6) , 2122
Open AccessReal-Time EEG-Derived Amygdala Neurofeedback for Post-Traumatic Stress Disorder: A Clinical Case Series
Background: Post-traumatic stress disorder (PTSD) affects millions globally, with 40–50% of patients not responding adequately to first-line treatments. Prism neurofeedback, an FDA-cleared electroencephalography (EEG)-based system targeting amygdala-derived biomarkers, has demonstrated efficacy in randomized controlled trials (RCTs) and multicenter studies. Real-world implementation data from community clinical practice remain limited. Objective: To evaluate clinical outcomes and patient-developed self-regulation strategies of Prism neurofeedback in patients with PTSD in community clinical practice. Methods: Retrospective case series of 28 consecutive patients with PTSD treated with Prism neurofeedback in a community psychiatry practice. The primary outcome was change in PTSD Checklist for DSM-5 (PCL-5) from baseline to end of treatment. Results: Twenty-one of 28 patients (75.0%) completed treatment. Mean PCL-5 reduction was 37.0 ± 18.2 points (Cohen’s d = 2.03). Response rates were 100% for any improvement and 90.5% for clinically significant improvement (≥10-point reduction). Five patients (23.8%) achieved excellent response with ≥50-point reduction. Limited follow-up data (1–3 months post-treatment) were available for three patients; two of three (67%) exceeded their end-of-treatment gains. Four patients receiving booster sessions showed continued improvement. Limitations: The uncontrolled, retrospective design precludes causal attribution of improvements to the intervention versus placebo effects or regression to the mean. The 25% early discontinuation rate may introduce attrition bias. Durability data are available for only three patients. Conclusions: This case series provides real-world evidence supporting the feasibility and potential clinical utility of Prism neurofeedback in community practice, with outcomes comparable to controlled studies and preliminary evidence of durable treatment effects. These findings complement existing RCT evidence by demonstrating successful implementation outside research settings.
- Open Access
- 15 December 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (5) , 2520-2529
An fMRI-informed EEG model of the amygdala is associated with salience network dynamics during naturalistic emotional stimulation
The amygdala-derived EEG-fMRI pattern (Amyg-EFP) is an EEG model of fMRI amygdala activity with demonstrated therapeutic implications in neurofeedback interventions aimed at emotion regulation. Yet, its distributed neural correlates and potential relevance for emotional processing, independent of active modulation by neurofeedback, remain unexplored. This study aimed to characterize the distributed brain activations captured by the Amyg-EFP during passive processing of naturalistic emotional stimuli. Using simultaneous EEG-fMRI during stimulation with emotional movie and music excerpts in 71 healthy participants, we examined the spatiotemporal coupling between the Amyg-EFP and fMRI activations across the brain. We further measured the correlation of the Amyg-EFP with individual emotional reactivity ratings of the movie stimuli. Results revealed a correspondence between Amyg-EFP signal modulation and salience-network dynamics, tracking the anterior insula, dorsal anterior cingulate cortex, and salience-coactivated amygdala subregions. This association was specific to the Amyg-EFP, as a control EFP derived from the ventral striatum showed a different coupling pattern. In addition, the Amyg-EFP, but not the control EFP, was associated with emotional reactivity ratings of movie stimuli. Together, these findings tie localized amygdala activity captured by the Amyg-EFP, with broader salience-network dynamics and with individual reactivity, during the processing of emotional stimuli. Thereby, this study highlights the relevance of the Amyg-EFP for emotional reactivity, and its potential as a target in brain-based interventions for psychiatric disorders characterized by emotional dysregulation.
- 15 December 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (5) , 2520-2529
Open AccessAn fMRI-informed EEG model of the amygdala is associated with salience network dynamics during naturalistic emotional stimulation
The amygdala-derived EEG-fMRI pattern (Amyg-EFP) is an EEG model of fMRI amygdala activity with demonstrated therapeutic implications in neurofeedback interventions aimed at emotion regulation. Yet, its distributed neural correlates and potential relevance for emotional processing, independent of active modulation by neurofeedback, remain unexplored. This study aimed to characterize the distributed brain activations captured by the Amyg-EFP during passive processing of naturalistic emotional stimuli. Using simultaneous EEG-fMRI during stimulation with emotional movie and music excerpts in 71 healthy participants, we examined the spatiotemporal coupling between the Amyg-EFP and fMRI activations across the brain. We further measured the correlation of the Amyg-EFP with individual emotional reactivity ratings of the movie stimuli. Results revealed a correspondence between Amyg-EFP signal modulation and salience-network dynamics, tracking the anterior insula, dorsal anterior cingulate cortex, and salience-coactivated amygdala subregions. This association was specific to the Amyg-EFP, as a control EFP derived from the ventral striatum showed a different coupling pattern. In addition, the Amyg-EFP, but not the control EFP, was associated with emotional reactivity ratings of movie stimuli. Together, these findings tie localized amygdala activity captured by the Amyg-EFP, with broader salience-network dynamics and with individual reactivity, during the processing of emotional stimuli. Thereby, this study highlights the relevance of the Amyg-EFP for emotional reactivity, and its potential as a target in brain-based interventions for psychiatric disorders characterized by emotional dysregulation.
- Open Access
- 28 September 2025
- Published by Elsevier in Psychiatry Research
- Vol. 353, 116752
Amygdala-targeted neurofeedback for dissociative symptoms in PTSD: Converging evidence from three independent studies
- 28 September 2025
- Published by Elsevier in Psychiatry Research
- Vol. 353, 116752
Open AccessAmygdala-targeted neurofeedback for dissociative symptoms in PTSD: Converging evidence from three independent studies
- Open Access
- 23 September 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (19) , 2388
Cost Effectiveness of Adjunctive Neurofeedback vs. Psychotherapy or Pharmacotherapy for Post-Traumatic Stress Disorder
Background: Neurofeedback shows promise as an adjunctive therapy for post-traumatic stress disorder (PTSD), but its cost effectiveness has not been studied. Objectives: To assess the cost and effectiveness of neurofeedback plus other therapies (NF + OT) vs. guideline therapies alone. Methods: TreeAge software was used to develop Markov models comparing NF + OT therapy to psychotherapy and pharmacotherapy over 1–3 years. Costs were derived from Medicare rates and literature. Effectiveness was measured using CAPS-5 score reductions converted to quality-adjusted life years (QALYs) using regression analysis. Dropout and relapse rates were derived from systematic reviews and meta-analysis. Results: NF + OT resulted in greater improvements in CAPS-5 scores and was less costly than OT. In the base case, NF + OT was less expensive (on average) for years 1–3 by USD 2568−USD 4140 (vs. psychotherapy) and USD 2282−USD 7217 (vs. pharmacotherapy). QALYs improved by 0.04 compared to psychotherapy and 0.24 compared to pharmacotherapy. NF + OT dominated (lower cost, better outcomes) psychotherapy 12% of the time and pharmacotherapy 26.5% of the time in Monte Carlo simulation. Further, Monte Carlo simulation did not demonstrate dominance at any point in time for either pharmacotherapy or psychotherapy over NF + OT. Conclusions: Based on lower costs and improved effectiveness, NF + OT should be considered for treating PTSD.
- 23 September 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (19) , 2388
Open AccessCost Effectiveness of Adjunctive Neurofeedback vs. Psychotherapy or Pharmacotherapy for Post-Traumatic Stress Disorder
Background: Neurofeedback shows promise as an adjunctive therapy for post-traumatic stress disorder (PTSD), but its cost effectiveness has not been studied. Objectives: To assess the cost and effectiveness of neurofeedback plus other therapies (NF + OT) vs. guideline therapies alone. Methods: TreeAge software was used to develop Markov models comparing NF + OT therapy to psychotherapy and pharmacotherapy over 1–3 years. Costs were derived from Medicare rates and literature. Effectiveness was measured using CAPS-5 score reductions converted to quality-adjusted life years (QALYs) using regression analysis. Dropout and relapse rates were derived from systematic reviews and meta-analysis. Results: NF + OT resulted in greater improvements in CAPS-5 scores and was less costly than OT. In the base case, NF + OT was less expensive (on average) for years 1–3 by USD 2568−USD 4140 (vs. psychotherapy) and USD 2282−USD 7217 (vs. pharmacotherapy). QALYs improved by 0.04 compared to psychotherapy and 0.24 compared to pharmacotherapy. NF + OT dominated (lower cost, better outcomes) psychotherapy 12% of the time and pharmacotherapy 26.5% of the time in Monte Carlo simulation. Further, Monte Carlo simulation did not demonstrate dominance at any point in time for either pharmacotherapy or psychotherapy over NF + OT. Conclusions: Based on lower costs and improved effectiveness, NF + OT should be considered for treating PTSD.
- Open Access
- 27 May 2025
- Published by Elsevier in Psychiatry Research
- Vol. 350, 116567
Safety and efficacy of Deep TMS for adolescent depression based on large real-world data analysis
- 27 May 2025
- Published by Elsevier in Psychiatry Research
- Vol. 350, 116567
Open AccessSafety and efficacy of Deep TMS for adolescent depression based on large real-world data analysis
- Open Access
- 29 April 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (5) , 476
Reward System EEG–fMRI-Pattern Neurofeedback for Major Depressive Disorder with Anhedonia: A Multicenter Pilot Study
Background/Objectives: Up to 75% of patients with major depressive disorder (MDD) exhibit persistent anhedonia symptoms related to abnormalities in the positive valence system. Cumulative evidence points to brain dysfunction in the reward system (RS), including in the ventral striatum, in patients with MDD with anhedonia. This study aims to evaluate the safety and efficacy of a novel neurofeedback (NF) device (termed Prism) which incorporates the EEG–FRI-Pattern biomarker of the reward system (RS-EFP) for use in self-neuromodulation training (RS-EFP-NF) for alleviating depression in patients with MDD with anhedonia. Methods: A total of 49 adults (age range: M = 39.9 ± 11.03) with a DSM-5 diagnosis of MDD with anhedonia (per a SHAPS-C score ≥ 25) were screened for the administration of ten sessions of RS-EFP-NF twice a week on nonconsecutive days. Depression and anhedonia severity was assessed, respectively, by HDRS-17 and SHAPS-C at baseline, midway, and treatment end. Results: A total of 34 patients (77%) completed the protocol and were included in the analyses. No device-related adverse events were serious or required treatment. Depression symptoms were reduced at end of treatment as indicated by the HDRS-17, with a reduction of eight points on average (95% CI: −10.5 to −5.41, p < 0.0001), a clinical improvement rate of 78.47%, and a remission rate of 32.25%. Anhedonia, as indicated by the SHAPS-C score, was diminished, showing an average reduction of 6.3 points (95% CI: −8.51 to −4.14, p < 0.0001). Conclusions: Self-neuromodulation using RS-EFP-NF is a promising and safe treatment for MDD with anhedonia. The intervention demonstrates substantial clinical effects on both depression and anhedonia symptoms, with high patient acceptability and retention. Prism may address a critical mechanism-driven treatment gap for anhedonia that often persists despite conventional therapies. Larger controlled implementation, efficacy, and dosing studies are warranted.
- 29 April 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (5) , 476
Open AccessReward System EEG–fMRI-Pattern Neurofeedback for Major Depressive Disorder with Anhedonia: A Multicenter Pilot Study
Background/Objectives: Up to 75% of patients with major depressive disorder (MDD) exhibit persistent anhedonia symptoms related to abnormalities in the positive valence system. Cumulative evidence points to brain dysfunction in the reward system (RS), including in the ventral striatum, in patients with MDD with anhedonia. This study aims to evaluate the safety and efficacy of a novel neurofeedback (NF) device (termed Prism) which incorporates the EEG–FRI-Pattern biomarker of the reward system (RS-EFP) for use in self-neuromodulation training (RS-EFP-NF) for alleviating depression in patients with MDD with anhedonia. Methods: A total of 49 adults (age range: M = 39.9 ± 11.03) with a DSM-5 diagnosis of MDD with anhedonia (per a SHAPS-C score ≥ 25) were screened for the administration of ten sessions of RS-EFP-NF twice a week on nonconsecutive days. Depression and anhedonia severity was assessed, respectively, by HDRS-17 and SHAPS-C at baseline, midway, and treatment end. Results: A total of 34 patients (77%) completed the protocol and were included in the analyses. No device-related adverse events were serious or required treatment. Depression symptoms were reduced at end of treatment as indicated by the HDRS-17, with a reduction of eight points on average (95% CI: −10.5 to −5.41, p < 0.0001), a clinical improvement rate of 78.47%, and a remission rate of 32.25%. Anhedonia, as indicated by the SHAPS-C score, was diminished, showing an average reduction of 6.3 points (95% CI: −8.51 to −4.14, p < 0.0001). Conclusions: Self-neuromodulation using RS-EFP-NF is a promising and safe treatment for MDD with anhedonia. The intervention demonstrates substantial clinical effects on both depression and anhedonia symptoms, with high patient acceptability and retention. Prism may address a critical mechanism-driven treatment gap for anhedonia that often persists despite conventional therapies. Larger controlled implementation, efficacy, and dosing studies are warranted.
- Open Access
- 2 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2421
Amygdala EFP Neurofeedback Effects on PTSD Symptom Clusters and Emotional Regulation Processes
Background: Post-traumatic stress disorder (PTSD) manifests through distinct symptom clusters that can respond differently to treatments. Neurofeedback guided by the Amygdala-derived-EEG-fMRI-Pattern (Amyg-EFP-NF) has been utilized to train PTSD patients to regulate amygdala-related activity and decrease symptoms. Methods: We conducted a combined analysis of 128 PTSD patients from three clinical trials of Amyg-EFP-NF to evaluate effects across symptom clusters (as assessed by CAPS-5 subscales) and on emotion regulation processing (evaluated by the ERQ). Results: Amyg-EFP-NF significantly reduced severity across all PTSD symptom clusters immediately post-treatment, with improvements maintained at three-month follow-up. The arousal and reactivity cluster showed continued significant improvement during follow-up. Combined effect sizes were large (η2p = 0.23–0.35) across all symptom clusters. Regression analysis revealed that emotion regulation processes significantly explained 17% of the variance in symptom improvement during the follow-up period. Conclusions: Reduction of PTSD symptoms following Amyg-EFP-NF occurs across all symptom clusters, with emotional regulation processes potentially serving as an underlying mechanism of action. These results support Amyg-EFP-NF as a comprehensive treatment approach for PTSD that continues to show benefits after treatment completion.
- 2 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2421
Open AccessAmygdala EFP Neurofeedback Effects on PTSD Symptom Clusters and Emotional Regulation Processes
Background: Post-traumatic stress disorder (PTSD) manifests through distinct symptom clusters that can respond differently to treatments. Neurofeedback guided by the Amygdala-derived-EEG-fMRI-Pattern (Amyg-EFP-NF) has been utilized to train PTSD patients to regulate amygdala-related activity and decrease symptoms. Methods: We conducted a combined analysis of 128 PTSD patients from three clinical trials of Amyg-EFP-NF to evaluate effects across symptom clusters (as assessed by CAPS-5 subscales) and on emotion regulation processing (evaluated by the ERQ). Results: Amyg-EFP-NF significantly reduced severity across all PTSD symptom clusters immediately post-treatment, with improvements maintained at three-month follow-up. The arousal and reactivity cluster showed continued significant improvement during follow-up. Combined effect sizes were large (η2p = 0.23–0.35) across all symptom clusters. Regression analysis revealed that emotion regulation processes significantly explained 17% of the variance in symptom improvement during the follow-up period. Conclusions: Reduction of PTSD symptoms following Amyg-EFP-NF occurs across all symptom clusters, with emotional regulation processes potentially serving as an underlying mechanism of action. These results support Amyg-EFP-NF as a comprehensive treatment approach for PTSD that continues to show benefits after treatment completion.